ANGPTL4

ANGPTL4

A gene on chromosome 19p13.3 that encodes angiopoietin-like protein 4, which is expressed in endothelial cells in response to hypoxia. It is directly involved in regulating glucose homeostasis, lipid metabolism and insulin sensitivity; it may act as a regulator of angiogenesis and modulate tumourigenesis, and may protect endothelial cells by secreted factors. It reduces endothelial cell motility and inhibits sprouting and tube formation.
Mentioned in ?
References in periodicals archive ?
Reported the identification of a potential new drug target, angiopoietin-like protein 4 (ANGPTL4), and preclinical results demonstrating that antibodies directed to ANGPTL4 rapidly lower triglycerides and cholesterol.
This press release contains "forward-looking statements," including statements relating to the agreement with Invus to invest in Lexicon and Lexicon's research and development of LX6171, LX1031, LX1032 and ANGPTL4 antibodies.
Research suggests that a monoclonal antibody (mAb) targeting ANGPTL4 may have therapeutic application in the treatment of cardiovascular disease.
Lexicon scientists first identified ANGPTL4 as a potential target for cardiovascular disease using the company's proprietary gene knockout technology.
Earlier this year, researchers at the University of Texas Southwestern Medical Center in Dallas, the Institute of Molecular Medicine at the University of Texas Health Science Center in Houston, and other collaborating institutions found that individuals with a mutated ANGPTL4 gene have significantly lower triglyceride levels and higher levels of HDL cholesterol (or "good" cholesterol).
Lexicon has already generated versions of ANGPTL4 monoclonal antibodies that are currently in preclinical evaluation to identify a potential clinical development candidate.